SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 67.93-1.3%Jan 21 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen2/12/2007 12:42:17 PM
   of 347
 
"African Gene" Found

Contact: David W. Moskowitz MD
CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com

ST. LOUIS—February 12, 2007—GenoMed® (OTC Pink Sheets GMED), a Next Generation Disease Management company, announced today that it has found the "African gene," responsible for the much higher incidence of diabetes, high blood pressure, and kidney failure among people of African ancestry than whites.

High blood pressure, and many other diseases, are roughly twice as common among African Americans than whites. For people with high blood pressure, kidney failure is five times more common among African Americans than whites. So blacks have 10 times more kidney failure than whites. The difference has been ascribed to the "African gene."

The "African gene," or more accurately, "African genotype," is actually a misnomer. It is not unique to Africans, but is present in every ethnic group, where it appears to cause most common diseases. (It is just more frequent among Africans). For example, it is associated with three-quarters of common diseases among whites. GenoMed has shown that knowing this "master" disease gene makes it possible to prevent kidney failure in whites, blacks, and Hispanics.

Said Dr. David Moskowitz, GenoMed's CEO, "It is appropriate that this February, Black History Month, we start trying to make kidney dialysis a thing of the past, since African Americans disproportionately make up the rolls of dialysis companies. So do other people of color: Hispanics and Native Americans have much more diabetes and kidney failure than whites."

Dr. Moskowitz continued, "The advantage of knowing the gene behind most common diseases is obvious. In this case, society is fortunate to already have safe, effective, cheap generic drugs that work against the gene. Our only problem for the past five years has been in getting the word out."

Dr. Moskowitz has published extensively on the African gene in peer-reviewed medical journals beginning in 1996.

About GenoMed

GenoMed estimates that it can already save 10% of healthcare costs and extend life by 5 years. Patients are encouraged to contact Dr. Moskowitz (dwmoskowitz@genomed.com) about joining GenoMed's Clinical Outcomes Improvement Program (COIP®).

.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext